US 12,441,992 B2
Method of treating AML with PEGylated l-asparaginase
Thierry Abribat, Sainte Foy les Lyon (FR)
Assigned to Jazz Pharmaceuticals II SAS, Lyons (FR)
Filed by JAZZ PHARMACEUTICALS II SAS, Lyons (FR)
Filed on Jun. 3, 2021, as Appl. No. 17/338,508.
Application 16/877,324 is a division of application No. 15/886,216, filed on Feb. 1, 2018, abandoned.
Application 17/338,508 is a continuation of application No. 16/877,324, filed on May 18, 2020, granted, now 11,046,946.
Application 15/886,216 is a continuation of application No. 14/819,305, filed on Aug. 5, 2015, granted, now 9,920,311, issued on Mar. 20, 2018.
Application 14/819,305 is a continuation of application No. 13/382,276, abandoned, previously published as PCT/EP2010/059599, filed on Jul. 6, 2010.
Claims priority of provisional application 61/223,320, filed on Jul. 6, 2009.
Prior Publication US 2021/0348151 A1, Nov. 11, 2021
Int. Cl. C12N 9/82 (2006.01); A61K 38/50 (2006.01); A61K 47/60 (2017.01); C12N 9/96 (2006.01)
CPC C12N 9/82 (2013.01) [A61K 38/50 (2013.01); A61K 47/60 (2017.08); C12N 9/96 (2013.01); C12Y 305/01001 (2013.01); Y02A 50/30 (2018.01)] 44 Claims
 
1. A method of treating acute myelocytic leukemia (AML) in a human patient, comprising: administering to the human patient an effective amount of a conjugate comprising four L-asparaginase monomers, wherein each of the monomers has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and is conjugated to at least one polyethylene glycol (PEG) molecule,
wherein each of the at least one PEG molecule has a molecular weight of about 2000 Da to about 5000 Da;
wherein each of the monomers comprises accessible amino groups, wherein about 100% of the accessible amino groups in the monomers are covalently linked to the PEG molecule;
and
wherein the human patient had previous hypersensitivity to an Escherichia coli L-asparaginase or a PEGylated form of an Escherichia coli L-asparaginase.